An Investigation Of The Epstein-Barr Virus Serological Status In The Adult Population

Milica Mladenović; Aleksandra Knežević

doi:10.5937/mp76-55980

Milica Mladenović Medicinski fakultet Univerziteta u Beogradu
Aleksandra Knežević Institute for Microbiology and Immunology, University of Belgrade Faculty of Medicine

DOI: https://doi.org/10.5937/mp76-55980

Keywords: Epstein-Barr virus; seroprevalence; latency; anti-EBV antibodies

Abstract

Introduction: Epstein-Barr virus is an ubiquitous virus from the family Herpesviridae, with seroprevalence ˃90% of world population. Primary infection is asymptomatic or in the form of infectious mononucleosis, depending on the age of patient and immune status. EBV establishes a latent infection in B-lymphocytes with occasional reactivation and because of its oncogenic potential, there is an association with numerous malignancies. Data on the EBV seroprevalence in our population is scarce.

Аim: The aim of the study is to investigate the EBV serological status in the adult population by detecting specific antibodies against viral antigens.

Material and methods: Serum samples of 58 individuals (age: 30.8±13.7 years; gender: M=41.4%, F=58.6%) were tested with comercial ELISA kits for presence of four antibodies against EBV (anti-VCA-IgM, anti-VCA-IgG, anti-EA-IgG, anti-EBNA-IgG). Based on recommendations from literature, every patient was, depending on serology results, classified in appropriate profile of EBV infection (primary, latent, reactivation).

Results: In the 89.5% serum samples, antibodies against EBV were detected, with increasing trend of seropositive patients with age: from 87% seropositive samples in population 18-30 years, to 100% in elderly population. The profile of latent infection was detected in 81% of patients, 3.4% profile of primary infection, 3.4% profile of reactivated infection and 1.7% of unknown profile. There was no significant difference (p˃0.05) between titers of anti-VCA-IgG or anti-EBNA-IgG antibodies in different age groups, nor between genders. The significant difference was not found (p˃0.05) in the number of EBV seropositive samples between genders nor between age groups.

Conclusion: Our study showed a high rate of latent EBV infection of 81%, which stipulates high grade of EBV infection in studied population. Differeneces in the seroprevalence among genders weren’t found nor among different age groups. Follow-up investigation of EBV seroprevalence in our population is needed in order to monitor the number of reactivated infections and development of malignancies associated with EBV.

Keywords: Epstein-Barr virus; seroprevalence; latency; anti-EBV antibodies

Author Biography

Aleksandra Knežević, Institute for Microbiology and Immunology, University of Belgrade Faculty of Medicine

- Full professor in the Department for Medical Microbiology

- Virusology

References

1. Sarwari NM, Khoury JD, Rojas Hernandez CM. Chronic Epstein Barr virus infection leading to classical Hodgkin lymphoma. BMC Hematology. 2016; 16:19.
2. Keiji I, Takenobu Y, Kazuhide T, Daisuke S, Kazuyasu F, Hironori M, et al. A Spectrum of Clinical Manifestations Caused by Host Immune Responeses against Epstein-Barr Virus Infections. Acta.med. Okayama. 2004; 58(4):169-180.
3. Odumade OA, Hogquist KA, Balfour HH. Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections. Clinical Microbiology Reviews. 2011; 24(1):193-209.
4. Tempera I, Lieberman P. Epigenetic regulation of EBV Persistence and Oncogenesis. Semin Cancer biol. 2014; 0:22-29.
5. Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Frontiers in Oncology. 2018; 8(211).
6. Figuera-Silva CM, Pereira FE. Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitoria, State of Espirito Santo, Brazil. Revista da Sociedade Brasileira de Medicina Tropical. 2004; 37(5):409-412.
7. Balfour HH, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. Age-Specific Prevalence of Epstein –Barr Virus Infection Among Individuals Aged 6-19 Years in the Unites States and Factors Affecting Its Acquisition. The Journal of Infectious Diseases. 2013; 208(8).
8. Brkić S, Jovanović J, Preveden T, Vukobratov Z. Serološki profil Epstein-Barr virusne infekcije u akutnoj infektivnoj mononukleozi. Med Pregl. 2003; 56(1-2):7-16.
9. Lindsey JW, Hatfield LM, Vu T. Epstein-Barr virus neutralizing and early antigen antibodies in multiple sclerosis. Eur J Neurol. 2010; 17(10):1263-1269.
10. Draborg AH, Jergensen JM, Muller H, Nielsen CT, Jacobsen S, Iversen LV, et al. Epstein-Barr virus early antigen diffuse (EBV-EA/D)-direct immunoglobulin A antibodies in systematic lupus erythematosus patients. Scand J Rheumatol. 2012; 41:280-289.
11. Jiang Y, Zilioli S, Stowe R, Rubinstein R, Peek K, Cutchin M. Perceived social support and latent herpesvirus reactivation: Testing main and stress-buffering effects in an ethnically diverse sample od adults. Psychosom Med. 2021; 83(7):767-776.
12. Smatti MK, Yassine HM, AbuOdeh R, AlMarawani A, Taleb SA, Althani A, et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PloS ONE. 2017; 12(12): e0189033.
13. Eksi F, Karsligil T, Erinmez M, Pehlivan M. Investigation of Epstein-Barr Virus antibodies by ELISA and IFA methods. J Exp Clin Med. 2022; 39(1):66-70.
14. Sharifipour S, Rad KD. Seroprevalence of Epstein-Barr virus among children and adults in Tehran, Iran. New Microbes and New Infections. 2020; 34(C).
15. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV and EBV among thr general population in Ghana, West Africa. BMC Infectious diseases. 2008; 8:111.
16. Wnter JR, Taylor GS, Thomas OG, Jackson C, Lewis JEA, Stagg HR. Predictors of Epstein-Barr virus serostatus in young people in England. BMC Infectious diseases. 2019; 1007.
17. Klutts JS, Ford BA, Perez NR, Gronowski AM. Evidence-Based Approach for Interpretation of Epstein-Barr Virus Serological Patterns. Journal of Clinical Microbiology. 2009; 3204-3210.
18. Freitas LF, Silva JM, Barbosa AN, Pinheiro-Silva R, Pontes GS. Epidemiological and Liver Biomarkers Profile of Epstein-Barr Virus Infection and Its Coinfection with Cytomegalovirus in Patients with Hematological Diseases. Biomolecules. 2021; 11:1151..
19. Abrahamyan S, Eberspaccher B, Hoshi M-M, Aly L, Luessi F, Groppa S et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020; 91:681-686.
20. Wood RA, Guthridge L, Turmond E, Guthridge CJ, Kheir JM, Bourn RL et al. Serologic markers of Epstein-Barr virus reactivation with increased disease activity, inflammation, and interferon pathway activation in patients with systematic lupus erythomatosus. Journal of translational autoimmunity. 2021; 4:100117.
21. Sausen DG, Bhutta MD, Gallo ES, Dahari H, Borenstein R. Stress-Induced Epstein-Barr Virus Reactivation. Biomolecules. 2021; 11:1380.
22. Balfour HH, Meirhaeghe MR, Stancari A, Geris JM, Condon L, Cederberg LE. Declining Epstein-Barr Virus Antibody prevalence in College Freshmen Strengthens the Rationale for a Profilactic EBV Vaccine. Vaccines. 2022; 10:1399.
23. Fourcade G, Germi R, Guerber F, Lupo J, Baccard M, Seigneurin A et al. Evolution of EBV seroprevalence and primary infection age in French hospital and city laboratory network 2000-2016. PloS ONE. 2017; 12(4):e0175574.
24. Beader N, Kolarić B, Slačanac D, Tabain I, Vilibić-Čavlek T. Seroepidemiological Study of Epstein-Barr Virus in Different Population Groups in Croatia. IMAJ. 2018; 20.